Altered Blood–Brain Barrier Dynamics in the C9orf72 Hexanucleotide Repeat Expansion Mouse Model of Amyotrophic Lateral Sclerosis

For peripherally administered drugs to reach the central nervous system (CNS) and treat amyotrophic lateral sclerosis (ALS), they must cross the blood–brain barrier (BBB). As mounting evidence suggests that the ultrastructure of the BBB is altered in individuals with ALS and in animal models of ALS...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Yijun Pan, Yoshiteru Kagawa, Jiaqi Sun, Bradley J. Turner, Cheng Huang, Anup D. Shah, Ralf B. Schittenhelm, Joseph A. Nicolazzo
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2022-12-01
Saila:Pharmaceutics
Gaiak:
Sarrera elektronikoa:https://www.mdpi.com/1999-4923/14/12/2803